Point72 Asset Management
PTCT icon

Point72 Asset Management’s PTC Therapeutics PTCT Stock Holding History

Point72 Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-94,800
Closed -$2.9M – 2266
2024
Q2 		$2.9M Buy
+94,800
New +$3.07M 0.01% 996
2017
Q2 		– Sell
-300,000
Closed -$2.95M – 970
2017
Q1 		$2.95M Buy
+300,000
New +$3.63M 0.02% 619

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management's PTCT Position: Q1 2026 in Review

Point72 Asset Management sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 1,128,551 shares — an estimated $85.7M sold.

Point72 Asset Management first reported a position in PTCT in Q3 2014 and held it in 29 quarters. The position peaked at $119M in Q2 2019. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Point72 Asset Management reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 1,128,551 PTC Therapeutics shares in Q1 2026, an estimated $85.7M.
  • Point72 Asset Management first reported a position in PTC Therapeutics in Q3 2014 and held it in 29 quarters.
  • Point72 Asset Management's PTC Therapeutics position peaked at $119M in Q2 2019.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.